Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Erbitux" drug pipelines has been added to ResearchAndMarkets.com's offering.

Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The receptor is involved in the regulation of cell growth, proliferation, and differentiation.

Erbitux is composed of the Fv regions of a murine EGFR MAb-specific for the N-terminal portion of human EGFR with human immunoglobulin G1 heavy and k-light chain constant regions. Binding of Erbitux to EGFR interferes with ligand-mediated activation of the receptor's intracellular tyrosine kinase activity and inhibits the EGFR-mediated signaling.

This results in the inhibition of cell growth, induction of apoptosis, decreased matrix metalloprotease secretion, and reduced vascular endothelial growth factor production. Erbitux may also induce the activation of the immune system through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Product Profiles

List of Figures

Figure 1: Erbitux for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Erbitux for colorectal cancer

Figure 3: Drug assessment summary of Erbitux for colorectal cancer

Figure 4: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

Figure 5: Erbitux for head and neck cancer - SWOT analysis

Figure 6: Drug assessment summary of Erbitux for SCCHN

Figure 7: Drug assessment summary of Erbitux for SCCHN

Figure 8: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Erbitux drug profile

Table 2: Overview of major approvals for Erbitux in colorectal cancer

Table 3: Erbitux Phase III data in colorectal cancer

Table 4: Erbitux Phase III data in colorectal cancer

Table 5: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 6: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25

Table 7: Erbitux drug profile

Table 8: Erbitux pivotal trial data in head and neck cancer

Table 9: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 10: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bttf3v/erbitux?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs , Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs , Skin Cancer Drugs